title: Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia.
abstract: The neuronal mechanisms underlying social withdrawal, one of the core negative symptoms of schizophrenia, are not well understood. Recent studies suggest an involvement of the endocannabinoid system in the pathophysiology of schizophrenia and, in particular, of negative symptoms. We used biochemical, pharmacological, and behavioral approaches to investigate the role played by the endocannabinoid system in social withdrawal induced by sub-chronic administration of phencyclidine (PCP). Pharmacological enhancement of endocannabinoid levels via systemic administration of URB597, an inhibitor of endocannabinoid degradation, reversed social withdrawal in PCP-treated rats via stimulation of CB1 receptors, but reduced social interaction in control animals through activation of a cannabinoid/vanilloid-sensitive receptor. In addition, the potent CB agonist CP55,940 reversed PCP-induced social withdrawal in a CB₁-dependent manner, whereas pharmacological blockade of CB₁ receptors by either AM251 or SR141716 reduced the time spent in social interaction in control animals. PCP-induced social withdrawal was accompanied by a decrease of anandamide (AEA) levels in the amygdala and prefrontal cortex, and these deficits were reversed by URB597. As CB₁ receptors are predominantly expressed on GABAergic interneurons containing the anxiogenic peptide cholecystokinin (CCK), we also examined whether the PCP-induced social withdrawal resulted from deficient CB₁-mediated modulation of CCK transmission. The selective CCK2 antagonist LY225910 blocked both PCP- and AM251-induced social withdrawal, but not URB597 effect in control rats. Taken together, these findings indicate that AEA-mediated activation of CB₁ receptors is crucial for social interaction, and that PCP-induced social withdrawal results from deficient endocannabinoid transmission.
authors.affiliation: Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA. seillier@uthscsa.edu
authors.forename: Alexandre
authors.initials: A
authors.lastname: Seillier
authors.forename: Alex A
authors.initials: AA
authors.lastname: Martinez
authors.forename: Andrea
authors.initials: A
authors.lastname: Giuffrida
mesh_terms: D000581:Amidohydrolases / Q000037:antagonists & inhibitors; D000679:Amygdala / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D001549:Benzamides / Q000494:pharmacology; D063386:Cannabinoid Receptor Agonists / Q000494:pharmacology; D063387:Cannabinoid Receptor Antagonists / Q000494:pharmacology; D002219:Carbamates / Q000494:pharmacology; D003511:Cyclohexanols / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D063388:Endocannabinoids / Q000378:metabolism / Q000502:physiology*; D008297:Male; D010622:Phencyclidine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010880:Piperidines / Q000037:antagonists & inhibitors / Q000494:pharmacology; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism; D011720:Pyrazoles / Q000037:antagonists & inhibitors / Q000494:pharmacology; D052999:Quinazolinones / Q000494:pharmacology; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D043887:Receptor, Cholecystokinin B / Q000037:antagonists & inhibitors; D000077285:Rimonabant; D012559:Schizophrenia / Q000503:physiopathology*; D012919:Social Behavior; D000099252:Fatty Acid Amide Hydrolases
chemical_list: D000581:Amidohydrolases; D001095:Arachidonic Acids; D001549:Benzamides; D063386:Cannabinoid Receptor Agonists; D063387:Cannabinoid Receptor Antagonists; D002219:Carbamates; D003511:Cyclohexanols; D063388:Endocannabinoids; D010622:Phencyclidine; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D052999:Quinazolinones; D043884:Receptor, Cannabinoid, CB1; D043887:Receptor, Cholecystokinin B; D000077285:Rimonabant; D000099252:Fatty Acid Amide Hydrolases; C435663:2-(2-(5-bromo-1H-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3H)-quinazolinone; C571130:CNR1 protein, human; C500528:cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester; C103505:AM 251; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; C078814:anandamide
references.citation: Schizophr Res. 2006 Sep;86(1-3):284-90
references.pmid: 16806837
references.citation: J Physiol. 2012 Feb 15;590(4):715-24
references.pmid: 22219337
references.citation: Eur Neuropsychopharmacol. 2010 Jan;20(1):25-36
references.pmid: 19854030
references.citation: J Neurosci. 2012 Oct 24;32(43):14899-908
references.pmid: 23100412
references.citation: Neuroscience. 2012 Mar 1;204:38-52
references.pmid: 21884761
references.citation: Brain Res. 2004 Oct 29;1025(1-2):75-84
references.pmid: 15464747
references.citation: Neuropharmacology. 2004 Jun;46(7):966-73
references.pmid: 15081793
references.citation: Schizophr Res. 2011 Aug;130(1-3):222-7
references.pmid: 21624823
references.citation: J Physiol. 2011 Feb 15;589(Pt 4):891-902
references.pmid: 21173082
references.citation: J Pharmacol Exp Ther. 2009 May;329(2):708-17
references.pmid: 19197005
references.citation: J Neurosci. 2004 Nov 3;24(44):9953-61
references.pmid: 15525780
references.citation: Prostaglandins Leukot Essent Fatty Acids. 2010 Sep;83(3):131-6
references.pmid: 20667702
references.citation: Methods Find Exp Clin Pharmacol. 2007 May;29(4):291-301
references.pmid: 17609743
references.citation: Neuroimage. 2010 Oct 1;52(4):1505-13
references.pmid: 20406692
references.citation: Arch Gen Psychiatry. 2008 Jul;65(7):772-84
references.pmid: 18606950
references.citation: Am J Med Genet B Neuropsychiatr Genet. 2008 Apr 5;147(3):279-84
references.pmid: 18186055
references.citation: Int Rev Psychiatry. 2009 Apr;21(2):152-62
references.pmid: 19367509
references.citation: J Clin Psychopharmacol. 2009 Jun;29(3):255-8
references.pmid: 19440079
references.citation: Neurosci Lett. 2001 Mar 23;301(1):69-71
references.pmid: 11239718
references.citation: Int J Neuropsychopharmacol. 2010 Apr;13(3):373-86
references.pmid: 19607756
references.citation: J Neurosci. 2004 Aug 4;24(31):6939-45
references.pmid: 15295029
references.citation: Neuropsychopharmacology. 2004 Nov;29(11):2108-14
references.pmid: 15354183
references.citation: Psychopharmacology (Berl). 2009 Oct;206(2):313-24
references.pmid: 19652957
references.citation: Schizophr Res. 2004 Nov 1;71(1):61-4
references.pmid: 15374573
references.citation: J Neurosci. 2010 Apr 14;30(15):5136-48
references.pmid: 20392936
references.citation: Curr Psychiatry Rep. 2010 Dec;12(6):563-71
references.pmid: 20821286
references.citation: Pharmacol Biochem Behav. 2004 Mar;77(3):567-73
references.pmid: 15006468
references.citation: Schizophr Bull. 2010 Mar;36(2):359-69
references.pmid: 18644851
references.citation: J Neurochem. 2000 Apr;74(4):1627-35
references.pmid: 10737621
references.citation: Am J Psychiatry. 2004 Jun;161(6):975-84
references.pmid: 15169685
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60
references.pmid: 14751433
references.citation: Neuropharmacology. 2004 Jan;46(1):115-25
references.pmid: 14654103
references.citation: Schizophr Bull. 2010 Sep;36(5):1020-8
references.pmid: 19336392
references.citation: Behav Pharmacol. 2010 Dec;21(8):690-709
references.pmid: 20847646
references.citation: Mol Psychiatry. 2002;7(5):515-8
references.pmid: 12082570
references.citation: Eur Neuropsychopharmacol. 2008 Jan;18(1):34-40
references.pmid: 17669634
references.citation: Neuropharmacology. 2002 Sep;43(4):503-10
references.pmid: 12367597
references.citation: J Neural Transm (Vienna). 2007;114(8):1055-63
references.pmid: 17370106
references.citation: Nature. 2011 Jul 27;477(7363):171-8
references.pmid: 21796121
references.citation: Eur J Neurosci. 1999 Dec;11(12):4213-25
references.pmid: 10594647
references.citation: J Neurosci. 2005 Oct 19;25(42):9746-51
references.pmid: 16237178
references.citation: Nat Neurosci. 2011 Mar;14(3):345-50
references.pmid: 21278728
references.citation: Neuropsychopharmacology. 2011 Jul;36(8):1620-30
references.pmid: 21471953
references.citation: Prostaglandins Other Lipid Mediat. 2006 Dec;81(3-4):106-12
references.pmid: 17085319
references.citation: Neuroscience. 2001;103(1):9-15
references.pmid: 11311783
references.citation: Int J Neuropsychopharmacol. 2011 Feb;14(1):17-28
references.pmid: 20196921
references.citation: J Neurosci. 1996 Jun 15;16(12):3934-42
references.pmid: 8656287
references.citation: Curr Opin Neurobiol. 2012 Jun;22(3):537-44
references.pmid: 22079494
references.citation: Am J Psychiatry. 2005 Mar;162(3):495-506
references.pmid: 15741466
references.citation: Eur J Neurosci. 2004 Apr;19(7):1906-12
references.pmid: 15078564